Year: 2003
Type: article
Abstract: ver 1.5 million percutaneous coronary revascularisation procedures are performed annually world wide, most being intracoronary stenting.Despite enormous advances in devices, the major limitation is in-stent stenosis (ISS) (reviewed by Bennett and O'Sullivan 1 ).Although ISS rates are 10-20% in selected patients, we now stent total occlusions, saphenous vein bypass grafts, both angioplasty and ISS sites, diabetic patients, and small vessels.Thus, real ISS rates are much higher, up to 59% in some high risk lesions.Until recently, the only effective treatment for ISS was brachytherapy.Brachytherapy reduces target vessel revascularisation rates and binary restenosis rates, and increases minimum luminal diameters (MLDs) compared with control vessels, maintained to three years.1 Although effective, brachytherapy is not universally accepted, due predominantly to late thrombosis and the logistics of administering radioactivity.In contrast, drug eluting stents containing the immunosuppressive agent rapamycin and the antimitotic agent paclitaxel have shown encouraging reductions in ISS in de novo lesions, 2 3 and possibly in ISS lesions.This review examines the pathology of ISS and how drugs bound to stents interrupt the normal response to vessel injury. c MECHANISMS OF RESTENOSISOverdistension of the diseased vessel causes endothelial disruption, internal elastic lamina fracture, and medial dissection.Lumen enlargement is caused by a combination of plaque reduction (compression/embolisation), axial plaque redistribution towards the proximal and distal segments outside the stent, plaque extrusion, and vessel expansion.Many processes then contribute to restenosis (fig 1 and table 1). Elastic recoilThe human epicardial coronary arteries contain elastin fibres comprising the internal and external elastic laminae (IEL/EEL).Elastic recoil therefore follows overstretch, occurring between seconds and minutes following balloon deflation, resulting in up to 40% loss of luminal areas.Although both angioplasty and stenting produce overstretch injury, stenting significantly reduces acute recoil. Reorganisation of thrombusAngioplasty or stenting causes endothelial denudation and induces medial dissection.The consequent exposure of subintimal components such as collagen, Von Willebrand factor, fibronectin, and laminin causes platelet adherence and aggregation.Fibrin and platelets are deposited on stent struts early after implantation.The association of fibrin and platelets with neointimal accumulation and extensive neovascularisation at ISS sites suggests that organisation of mural thrombus promotes ISS. Neointimal formationArterial injury induces vascular smooth muscle cell (VSMC) proliferation and/or migration due to: (1) mechanical stretch, IEL rupture, and medial dissection; (2) endothelial denudation with exposure to circulating mitogens such as angiotensin II and plasmin; and (3) release of mitogens and cytokines from platelets, endothelial cells, VSMCs, and inflammatory cells.VSMCs are normally in the quiescent (G 0 ) phase of the cell cycle.In animal models, injury induces medial and then intimal cell cycle entry, following a wave of immediate early gene expression.Cells undergo either cell proliferation, migration or both, with subsequent synthesis of extracellular matrix and collagen, resulting in neointima formation.Neointimal formation is the major cause of ISS.Neointima increases up to three months after the procedure, with little change to six months, and a gradual reduction between six months and three years.However, the role of cell proliferation within the neointima remains controversial.Cell proliferation is low in specimens retrieved from ISS sites, although higher in ISS versus angioplasty restenosis sites.4 Although neointima formation after stenting is associated with medial disruption
Source: Heart
Author: Martin R Bennett
Institution: Addenbrooke's Hospital
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: British Heart Foundation
OpenAlex ID: W2069465511
